主要文件

查看所有文档

R3501

利福平

Name: 利福平
Brand: SIGMA

≥95% (HPLC), powder or crystals

别名:

3-(4-甲基-1-哌嗪基亚胺甲基)利福霉素SV, 利米定, 甲哌利福霉素

登录查看组织和合同定价。

选择尺寸

变更视图

关于此项目

经验公式（希尔记法）:

C₄₃H₅₈N₄O₁₂

化学文摘社编号:

13292-46-1

分子量:

822.94

UNSPSC Code:

51283601

NACRES:

NA.76

PubChem Substance ID:

57654590

EC Number:

236-312-0

Beilstein/REAXYS Number:

5723476

MDL number:

MFCD00151389

技术服务

需要帮助？我们经验丰富的科学家团队随时乐意为您服务。

让我们为您提供帮助

Quality Level

200

assay

≥95% (HPLC)

form

powder or crystals

color

Reddish-brown

pI

4.84

pKa

1.7 (4-hydroxyl group), 7.9 (4-piperazine nitrogen)

antibiotic activity spectrum

Gram-negative bacteria, Gram-positive bacteria, mycobacteria, viruses

mode of action

protein synthesis | interferes

storage temp.

−20°C

SMILES string

CO[C@H]1\C=C\O[C@@]2(C)Oc3c(C)c(O)c4c(O)c(NC(=O)C(C)=C\C=C\[C@H](C)[C@H](O)[C@@H](C)[C@@H](O)[C@@H](C)[C@H](OC(C)=O)[C@@H]1C)c(\C=N\N5CCN(C)CC5)c(O)c4c3C2=O

InChI

1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1

InChI key

JQXXHWHPUNPDRT-WLSIYKJHSA-N

正在寻找类似产品? 访问产品对比指南

General description

化学结构:大环内酯物

Application

利福平用于治疗结核病和与结核病相关的分枝杆菌感染。其广泛应用于自身免疫性胆汁淤积性肝病，原发性胆汁性肝硬化(PBC)的止痒剂。它已被证明会引起肝炎。

Biochem/physiol Actions

利福平抑制DNA和蛋白质组装成成熟的病毒颗粒。它通过与RNA聚合酶的亚基结合抑制RNA合成的起始，从而导致细胞死亡。

抑制DNA和蛋白质组装成成熟的病毒颗粒。

作用方式：通过与RNA聚合酶的β-亚基结合抑制RNA合成的起始。

Other Notes

保持容器密闭在干燥通风处。产品对光和湿度敏感。储存在惰性气体中。干燥处保存

pictograms

GHS07

signalword

Warning

hcodes

H302

pcodes

P264 - P270 - P301 + P312 - P501

Hazard Classifications

Acute Tox. 4 Oral

存储类别

11 - Combustible Solids

wgk

WGK 1

flash_point_f

Not applicable

flash_point_c

Not applicable

ppe

dust mask type N95 (US), Eyeshields, Gloves

法规信息

涉药品监管产品

此项目有

历史批次信息供参考:

分析证书(COA)

Lot/Batch Number

没有发现合适的版本？

如果您需要特殊版本，可通过批号或批次号查找具体证书。

搜索COA

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

Hepatitis and liver dysfunction with rifampicin therapy for pruritus in primary biliary cirrhosis.

M I Prince et al.

Gut, 50(3), 436-439 (2002-02-13)

There is evidence to suggest that rifampicin is an effective second line therapy for controlling pruritus in patients with chronic cholestatic liver disease. It is most widely used as an antipruritic agent in the autoimmune cholestatic liver disease, primary biliary

Potential market for novel tuberculosis diagnostics: worth the investment?

Sandra V Kik et al.

The Journal of infectious diseases, 211 Suppl 2, S58-S66 (2015-03-15)

The potential available market (PAM) for new diagnostics for tuberculosis that meet the specifications of the high-priority target product profiles (TPPs) is currently unknown. We estimated the PAM in 2020 in 4 high-burden countries (South Africa, Brazil, China, and India)

In vivo selection of reduced susceptibility to carbapenems in Acinetobacter baumannii related to ISAba1-mediated overexpression of the natural bla(OXA-66) oxacillinase gene.

Samy Figueiredo et al.

Antimicrobial agents and chemotherapy, 53(6), 2657-2659 (2009-03-25)

Two clonally related Acinetobacter baumannii isolates, A1 and A2, were obtained from the same patient. Isolate A2, selected after an imipenem-containing treatment, showed reduced susceptibility to carbapenems. This resistance pattern was related to insertion of the ISAba1 element upstream of

Detection of NDM-1-producing Klebsiella pneumoniae in Kenya.

Laurent Poirel et al.

Antimicrobial agents and chemotherapy, 55(2), 934-936 (2010-12-01)

Seven carbapenem-resistant NDM-1-positive Klebsiella pneumoniae isolates were recovered from patients hospitalized between 2007 and 2009 in different wards at a referral and tertiary care center in Nairobi. Most of the isolates were obtained from urine. All isolates carried the bla(NDM-1)

Efficiency and safety of the combination of moxifloxacin, pretomanid (PA-824), and pyrazinamide during the first 8 weeks of antituberculosis treatment: a phase 2b, open-label, partly randomised trial in patients with drug-susceptible or drug-resistant pulmonary tuberculosis.

Rodney Dawson et al.

Lancet (London, England), 385(9979), 1738-1747 (2015-03-22)

New antituberculosis regimens are urgently needed to shorten tuberculosis treatment. Following on from favourable assessment in a 2 week study, we investigated a novel regimen for efficacy and safety in drug-susceptible and multidrug-resistant (MDR) tuberculosis during the first 8 weeks

查看所有相关文献

商品

Critical Inhibitor Characteristics to Consider

Discover critical characteristics to consider when working with enzyme inhibitors, such as cell permeability, the prozone effect, and Lipinski’s rule of 5.

全球贸易项目编号

货号	GTIN
R3501-5G	04061835522484
R3501-25G	04061835548262
R3501-250MG	04061835513970
R3501-1G	04061835548255

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系客户支持